|Bid||39.11 x 800|
|Ask||39.21 x 1800|
|Day's Range||36.55 - 39.56|
|52 Week Range||16.00 - 75.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.86|
Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.